Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Bone Rep ; 18: 101647, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36636109

ABSTRACT

Subchondral bone participates in crosstalk with articular cartilage to maintain joint homeostasis, and disruption of either tissue results in overall joint degeneration. Among the subchondral bone changes observed in osteoarthritis (OA), subchondral bone plate (SBP) thickening has a time-dependent relationship with cartilage degeneration and has recently been shown to be regulated by osteocytes. Here, we evaluate the effect of age on SBP thickness and cartilage degeneration in aging mice. We find that SBP thickness significantly increases by 18-months of age, corresponding temporally with increased cartilage degeneration. To identify factors in subchondral bone that may participate in bone cartilage crosstalk or OA, we leveraged mouse transcriptomic data from one joint tissue compartment - osteocyte-enriched bone - to search for enrichment with human OA in UK Biobank and Arthritis Research UK Osteoarthritis Genetics (arcOGEN) GWAS using the mouse2human (M2H, www.mouse2human.org) strategy. Genes differentially expressed in aging mouse bone are significantly enriched for human OA, showing joint site-specific (knee vs. hip) relationships, exhibit temporal associations with age, and unique gene clusters are implicated in each type of OA. Application of M2H identifies genes with known and unknown functions in osteocytes and OA development that are clinically associated with human OA. Altogether, this work prioritizes genes with a potential role in bone/cartilage crosstalk for further mechanistic study based on their association with human OA in GWAS.

2.
Curr Rheumatol Rep ; 24(6): 184-197, 2022 06.
Article in English | MEDLINE | ID: mdl-35499698

ABSTRACT

PURPOSE OF REVIEW: The effect of the transforming growth factor beta (TGFß) signaling pathway on joint homeostasis is tissue-specific, non-linear, and context-dependent, representing a unique complexity in targeting TGFß signaling in joint disease. Here we discuss the variety of mechanisms that TGFß signaling employs in the synovial joint to maintain healthy joint crosstalk and the ways in which aberrant TGFß signaling can result in joint degeneration. RECENT FINDINGS: Osteoarthritis (OA) epitomizes a condition of disordered joint crosstalk in which multiple joint tissues degenerate leading to overall joint deterioration. Synovial joint tissues, such as subchondral bone, articular cartilage, and synovium, as well as mesenchymal stem cells, each demonstrate aberrant TGFß signaling during joint disease, whether by excessive or suppressed signaling, imbalance of canonical and non-canonical signaling, a perturbed mechanical microenvironment, or a distorted response to TGFß signaling during aging. The synovial joint relies upon a sophisticated alliance among each joint tissue to maintain joint homeostasis. The TGFß signaling pathway is a key regulator of the health of individual joint tissues, and the subsequent interaction among these different joint tissues, also known as joint crosstalk. Dissecting the sophisticated function of TGFß signaling in the synovial joint is key to therapeutically interrogating the pathway to optimize overall joint health.


Subject(s)
Cartilage, Articular , Osteoarthritis , Cartilage, Articular/metabolism , Humans , Osteoarthritis/metabolism , Signal Transduction , Synovial Membrane/metabolism , Transforming Growth Factor beta
3.
Arthritis Rheumatol ; 73(3): 414-425, 2021 03.
Article in English | MEDLINE | ID: mdl-33022131

ABSTRACT

OBJECTIVE: Transforming growth factor ß (TGFß) signaling plays a complex tissue-specific and nonlinear role in osteoarthritis (OA). This study was conducted to determine the osteocytic contributions of TGFß signaling to OA. METHODS: To identify the role of osteocytic TGFß signaling in joint homeostasis, we used 16-week-old male mice (n = 9-11 per group) and female mice (n = 7-11 per group) with an osteocyte-intrinsic ablation of TGFß receptor type II (TßRIIocy-/- mice) and assessed defects in cartilage degeneration, subchondral bone plate (SBP) thickness, and SBP sclerostin expression. To further investigate these mechanisms in 16-week-old male mice, we perturbed joint homeostasis by subjecting 8-week-old mice to medial meniscal/ligamentous injury (MLI), which preferentially disrupts the mechanical environment of the medial joint to induce OA. RESULTS: In all contexts, independent of sex, genotype, or medial or lateral joint compartment, increased SBP thickness and SBP sclerostin expression were spatially associated with cartilage degeneration. Male TßRIIocy-/- mice, but not female TßRIIocy-/- mice, had increased cartilage degeneration, increased SBP thickness, and higher levels of SBP sclerostin compared with control mice (all P < 0.05), demonstrating that the role of osteocytic TGFß signaling on joint homeostasis is sexually dimorphic. With changes in joint mechanics following injury, control mice had increased SBP thickness, subchondral bone volume, and SBP sclerostin expression (all P < 0.05). TßRIIocy-/- mice, however, were insensitive to subchondral bone changes with injury, suggesting that mechanosensation at the SBP requires osteocytic TGFß signaling. CONCLUSION: Our results provide new evidence that osteocytic TGFß signaling is required for a mechanosensitive response to injury, and that osteocytes control SBP homeostasis to maintain cartilage health, identifying osteocytic TGFß signaling as a novel therapeutic target for OA.


Subject(s)
Bone and Bones/metabolism , Cartilage, Articular/metabolism , Mechanotransduction, Cellular/genetics , Osteoarthritis/metabolism , Osteocytes/metabolism , Receptor, Transforming Growth Factor-beta Type II/genetics , Transforming Growth Factor beta/metabolism , Adaptor Proteins, Signal Transducing/metabolism , Animals , Bone and Bones/diagnostic imaging , Bone and Bones/pathology , Cartilage, Articular/pathology , Female , Hindlimb , Homeostasis , Male , Medial Collateral Ligament, Knee/surgery , Menisci, Tibial/surgery , Mice , Mice, Knockout , Osteoarthritis/diagnostic imaging , Osteoarthritis/pathology , Sex Factors , Signal Transduction , X-Ray Microtomography
4.
Bone Res ; 7: 34, 2019.
Article in English | MEDLINE | ID: mdl-31700695

ABSTRACT

Osteoarthritis (OA), long considered a primary disorder of articular cartilage, is commonly associated with subchondral bone sclerosis. However, the cellular mechanisms responsible for changes to subchondral bone in OA, and the extent to which these changes are drivers of or a secondary reaction to cartilage degeneration, remain unclear. In knee joints from human patients with end-stage OA, we found evidence of profound defects in osteocyte function. Suppression of osteocyte perilacunar/canalicular remodeling (PLR) was most severe in the medial compartment of OA subchondral bone, with lower protease expression, diminished canalicular networks, and disorganized and hypermineralized extracellular matrix. As a step toward evaluating the causality of PLR suppression in OA, we ablated the PLR enzyme MMP13 in osteocytes while leaving chondrocytic MMP13 intact, using Cre recombinase driven by the 9.6-kb DMP1 promoter. Not only did osteocytic MMP13 deficiency suppress PLR in cortical and subchondral bone, but it also compromised cartilage. Even in the absence of injury, osteocytic MMP13 deficiency was sufficient to reduce cartilage proteoglycan content, change chondrocyte production of collagen II, aggrecan, and MMP13, and increase the incidence of cartilage lesions, consistent with early OA. Thus, in humans and mice, defects in PLR coincide with cartilage defects. Osteocyte-derived MMP13 emerges as a critical regulator of cartilage homeostasis, likely via its effects on PLR. Together, these findings implicate osteocytes in bone-cartilage crosstalk in the joint and suggest a causal role for suppressed perilacunar/canalicular remodeling in osteoarthritis.

5.
Arthritis Res Ther ; 16(3): R134, 2014 Jun 25.
Article in English | MEDLINE | ID: mdl-24964765

ABSTRACT

INTRODUCTION: Post-traumatic arthritis (PTA) is a progressive, degenerative response to joint injury, such as articular fracture. The pro-inflammatory cytokines, interleukin 1(IL-1) and tumor necrosis factor alpha (TNF-α), are acutely elevated following joint injury and remain elevated for prolonged periods post-injury. To investigate the role of local and systemic inflammation in the development of post-traumatic arthritis, we targeted both the initial acute local inflammatory response and a prolonged 4 week systemic inflammatory response by inhibiting IL-1 or TNF-α following articular fracture in the mouse knee. METHODS: Anti-cytokine agents, IL-1 receptor antagonist (IL-1Ra) or soluble TNF receptor II (sTNFRII), were administered either locally via an acute intra-articular injection or systemically for a prolonged 4 week period following articular fracture of the knee in C57BL/6 mice. The severity of arthritis was then assessed at 8 weeks post-injury in joint tissues via histology and micro computed tomography, and systemic and local biomarkers were assessed in serum and synovial fluid. RESULTS: Intra-articular inhibition of IL-1 significantly reduced cartilage degeneration, synovial inflammation, and did not alter bone morphology following articular fracture. However, systemic inhibition of IL-1, and local or systemic inhibition of TNF provided no benefit or conversely led to increased arthritic changes in the joint tissues. CONCLUSION: These results show that intra-articular IL-1, rather than TNF-α, plays a critical role in the acute inflammatory phase of joint injury and can be inhibited locally to reduce post-traumatic arthritis following a closed articular fracture. Targeted local inhibition of IL-1 following joint injury may represent a novel treatment option for PTA.


Subject(s)
Interleukin-1/metabolism , Knee Injuries/metabolism , Knee Joint/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/blood , Antirheumatic Agents/pharmacology , Arthritis, Experimental/etiology , Arthritis, Experimental/metabolism , Arthritis, Experimental/prevention & control , Etanercept , Fractures, Closed/complications , Immunoglobulin G/administration & dosage , Immunoglobulin G/blood , Immunoglobulin G/pharmacology , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Injections, Intra-Articular , Interleukin 1 Receptor Antagonist Protein/administration & dosage , Interleukin 1 Receptor Antagonist Protein/blood , Interleukin 1 Receptor Antagonist Protein/pharmacology , Interleukin-1/antagonists & inhibitors , Intra-Articular Fractures/complications , Knee Injuries/etiology , Knee Injuries/prevention & control , Knee Joint/drug effects , Knee Joint/pathology , Male , Mice, Inbred C57BL , Receptors, Tumor Necrosis Factor/administration & dosage , Receptors, Tumor Necrosis Factor/blood , Synovitis/metabolism , Synovitis/prevention & control , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , X-Ray Microtomography
SELECTION OF CITATIONS
SEARCH DETAIL
...